7 news items
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
MAIA
7 Jun 24
investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
MAIA
7 Jun 24
for further investigation and potential redefinition of cancer treatment protocols.As THIO-101 data
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA
6 Jun 24
and investigators about our growing cancer treatment business."
THIO's dual mechanism of action is designed
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
CORT
HALO
MAIA
6 Jun 24
) is an investigational telomere-targeting agent designed to disrupt the survival mechanisms of cancer cells. By inducing telomerase-dependent DNA damage
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
MAIA
4 Jun 24
THIO (6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical
1f6i32ekuna84dlvgen1tz7vrixzouol
AFMD
ALBT
BPTH
4 Jun 24
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a pioneering investigational telomere-targeting agent
g1xmu
MAIA
17 May 24
THIO (6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently
- Prev
- 1
- Next